Cantor Fitzgerald Comments on JANX FY2025 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Cantor Fitzgerald issued their FY2025 earnings estimates for Janux Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($2.95) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $200.00 price target on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm’s revenue was down 82.6% on a year-over-year basis.

A number of other research firms have also recently commented on JANX. UBS Group initiated coverage on Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target for the company. HC Wainwright boosted their target price on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Stifel Nicolaus increased their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Scotiabank lifted their price target on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a report on Wednesday, December 4th. Finally, Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics currently has a consensus rating of “Buy” and an average target price of $89.90.

Janux Therapeutics Price Performance

Shares of JANX opened at $40.91 on Wednesday. The firm has a 50 day simple moving average of $52.59 and a two-hundred day simple moving average of $48.43. Janux Therapeutics has a one year low of $7.79 and a one year high of $71.71. The company has a market cap of $2.15 billion, a P/E ratio of -34.97 and a beta of 3.23.

Insider Transactions at Janux Therapeutics

In related news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the transaction, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at $15,101,171.16. The trade was a 8.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 13,334 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now owns 82,139 shares in the company, valued at $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 108,334 shares of company stock worth $6,070,020. Company insiders own 29.40% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Amalgamated Bank grew its holdings in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after acquiring an additional 368 shares during the period. Plato Investment Management Ltd boosted its position in shares of Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after purchasing an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares during the period. Avanza Fonder AB bought a new stake in Janux Therapeutics in the fourth quarter worth approximately $139,000. Finally, AQR Capital Management LLC bought a new stake in Janux Therapeutics in the second quarter worth approximately $215,000. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.